34 results about "Bacteremia" patented technology

The invention includes systems and methods to combine acoustic sorting, high-throughput imaging technology and machine learning, such as convolutional neural networks (ConvNet) analysis, to analyze cells, pathogens, and other target particles from biological samples resolvable by high-throughput imaging microscopy, or other comparable instrument.

The present application belongs to the field of microbial technology, and particularly relates to a bacteriophage preparation for controlling foodborne enterobacter and application thereof, wherein the bacteriophage preparation comprises any one or several of bacteriophage PhiEAS1, bacteriophage PhiEHO11, bacteriophage PhiEHO14 and bacteriophage PhiECL22. The four bacteriophages provided by the present application can be used alone or combined into a bacteriophage cocktail, and the influence of the bacteriophage preparation on enterobacter in different ecologies and environments is explored through bacteriophage cocktail therapy. The results show that the bacteriophage preparation exhibits significant bacteriostatic activity on various food substrates contaminated by Enterobacter hormaechei, such as lettuce, pork, milk, cherry tomato and the like; in an animal model, intraperitoneal injection of the bacteriophage preparation can effectively prevent and treat bacteremia caused by Enterobacter hormaechei, and shows potential as an anti-Enterobacter hormaechei biological control agent.

The invention belongs to the technical field of microorganisms, and particularly relates to a bacteriophage composition as well as application and a pharmaceutical composition thereof. The bacteriophage composition comprises the following bacteriophages: phi EBU8, phi ECL22 and phi EBU30, the key importance of early treatment in the aspect of treating enterobacter cloacae bacteremia by using the bacteriophage cocktail is proposed, and prophylactic administration possibly provides an opportunity for delayed treatment and rescue of bacteremia.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The disclosure provides a tebipenem pivoxil HBr formulation in the form of a tablet core comprising at least 70% (w / w) tebipenem pivoxil HBr, and in certain embodiment more than 80% (w / w) tebipenem pivoxil HBr. The disclosure provides a tebipenem pivoxil HBr tablet core comprising at least 70% w / w tebipenem pivoxil HBr, 5-25% w / w of a diluent, 0.5 to 5% w / w of a glidant, 0.5 to 5% w / w of a lubricant, and optionally 0.5 to 5% w / w of disintegrant. The disclosure provides methods of treating a patient who has a bacterial infection such as complicated urinary tract infection (cUTI), acute and chronic pyelonephritis, an upper or lower respiratory infection, or bacteremia by administering a formulation of the disclosure to the patient.

A method for assessing bacteremia includes the following steps. A blood analysis database is provided. A model establishing step is performed, wherein a plurality of reference cell population data, a plurality of reference complete blood counting data and a plurality of reference white blood cell differential counting data of the blood analysis database are trained to achieve a convergence by a machine learning algorithm model so as to obtain a bacteremia assessing classifier. A blood analysis data of a subject is provided, wherein the blood analysis data includes a cell population data, a complete blood counting data and a white blood cell differential counting data. An assessing step is performed, wherein the blood analysis data is analyzed by the bacteremia assessing classifier so as to obtain an assessing result of bacteremia of the subject.

Compositions and methods are provided for treating bacterial infections, including those that are challenging to treat by conventional medications, such as hospital acquired bacterial pneumonia (HABP), ventilator associated bacterial pneumonia (VABP), and bacteremia, caused by carbapenem-resistant bacteria such as Acinetobacter baumannii and Pseudomonas aeruginosa.

The present invention relates to aqueous ticagrelor solutions provided for intravenous administration for use in the treatment of a Gram-positive bacterial infection in the blood stream of a patient in need thereof. The invention is advantageous to further improve the effectiveness of bacteremia treatments, especially for MSSA and MRSA bacteremia and bacteremia-associated thrombocytopenia.

Provided herein are pharmaceutical compositions, therapeutic combinations, devices and methods for treating, ameliorating, reversing, causing the remission of, and / or preventing (acting as a prophylaxis, or preventing the initiation of) an inflammatory bowel disorder (IBD) or inflammatory bowel disease (IBD), Ulcerative Colitis; Crohn's disease; J-pouch; fistulising Crohn's disease; a Colitis which can be microscopic, lymphocytic or collagenous; an eosinophilic colitis; indeterminate colitis; idiopathic colitis; diverticulosis and diverticulitis; relapsing diverticulitis; constipation associated inflammatory bowel disease and / or small intestinal bacterial overgrowth; Irritable Bowel Syndrome (IBS) with or without diarrhoea, constipation or pain predominant IBS; periodontitis; rheumatoid arthritis; respiratory infections, appendicitis, vascular disorders such as thrombophlebitis; bacteremia; osteomyelitis; septic shock; Alzheimer's disease; Lemierre syndrome (postanginal sepsis); colonic polyps or adenomas (optionally hyperplastic, adenomatous or serrated adenomas) or preventing the growth of colonic polyps or adenomas, bowl cancer, or metastases (optionally preventing the initiation or promotion of bowl cancer or metastasis); pharyngitis; otitis; sinusitis; and any disease, symptom or condition caused or exacerbated by a Fusobacteria (optionally, a F. nucleatum or F. varium) infection. In alternative embodiments, pharmaceutical compositions comprise rifaximin alone or in combination with other antibiotics or drugs.

A diagnostic kit and method for detecting urinary tract infections (UTIs) and bacteremia using a drinking water test in low-resource settings is provided. The kit includes a first bag containing a first culture medium capable of detecting Gram-negative and coliform bacteria through colorimetric and fluorescence indicators, and a second bag containing a second culture medium capable of detecting Gram-positive bacteria through colorimetric indicators. A method of using the kit involves inoculating a sample into each bag, incubating the bags, and observing for color changes and fluorescence to indicate bacterial presence. The kit enables rapid, cost-effective detection of bacterial pathogens in urine and blood samples without specialized laboratory equipment, facilitating early diagnosis and treatment in resource-limited environments.

The invention provides enterococcus faecalis bacteriophage vBEfaS-1017 and application thereof, the enterococcus faecalis bacteriophage vBEfaS-1017 is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.46182, and the preservation time is September 6, 2024. The bacteriophage vBEfaS-1017 is high in specificity, short in incubation period and ultrahigh in stability, and has activity under the conditions of extreme pH, high temperature and ultraviolet radiation; by evaluating the in-vitro bactericidal efficacy of the bacteriophage vBEfaS-1017, it is determined that the bacteriophage vBEfaS-1017 can effectively remove a biological membrane formed by host bacteria Ef 10-17, the removal rate is as high as 90%, and the bacteriophage vBEfaS-1017 is expected to become a scavenger for solving the biological membrane. Further experiments prove that the bacteriophage vBEfaS-1017 has in-vivo and in-vitro safety. Through combined use of the bacteriophage and different antibiotics, it is found that combined use of the bacteriophage vBEfaS-1017 and the antibiotic levofloxacin can effectively treat bacteremia of mice, the treatment time after infection can be prolonged by using the bacteriophage in advance, and the bacteriophage has a good application prospect in the aspect of preventing and treating enterococcus faecalis.

The present invention relates to the field of antimicrobial agents, and in particular to quaternized norharman dimers, pharmaceutical compositions thereof, and antimicrobial uses. The present invention provides a quaternized norharman dimer, the MIC value of which against MRSA is 0.015 to 0.5 μg / mL, which is stronger than the clinical first-line drug vancomycin, and can be used to treat infectious diseases caused by MRSA, such as bacteremia, pneumonia, myocarditis, wound infection, bone and joint infection, etc. The quaternized norharman dimer is active against Gram-negative bacteria Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii at the same time, and has a broad-spectrum antibacterial characteristic.

The invention provides a pseudomonas aeruginosa bacteriophage and application thereof. The pseudomonas aeruginosa bacteriophage is a bacteriophage phi PA1019, is screened from sewage and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.46181, and the preservation time is September 6, 2024. Furthermore, a homologous recombination technology is utilized to modify the genome of the bacteriophage phi PA1019, and the PslG gene is introduced into the bacteriophage phi PA1019 to obtain the bacteriophage phi PA1019-PslG. The bacteriophage PhiPA1019 and the bacteriophage PhiPA1019-PslG disclosed by the invention both show extremely wide lysis activity and relatively high pH (Potential of Hydrogen) and temperature tolerance. The determination shows that the introduction of the PslG gene obviously enhances the ability of the bacteriophage in the aspects of inhibiting the growth and attachment of the biofilm and removing the biofilm; meanwhile, the treatment effect of the phage on bacteremia of mice is also researched, and the phage phi PA10-19-PslG is higher in cracking speed and stronger in capability on pseudomonas aeruginosa.

The present invention relates to phenylenediamine derivatives having certain pharmacological properties resulting from enhancing the epithelial barrier function and / or preventing bacterial translocation through the epithelial barrier. The compounds are useful in the treatment of various conditions, including conditions involving the displacement of pathogens from the gastrointestinal tract to the lower tissue and blood vessels, such as fever neutropenia, intestinal tissue inflammation, bacteremia, and sepsis.

The present invention discloses a method for large-scale extraction of extracellular membrane vesicles (OMV / FGF2) secreted by Escherichia coli that has ampicillin resistance and can secrete bFGF protein after gene editing. The method cultured Escherichia coli in LB liquid containing 100ug / mL ampicillin, and used ultrasonic separation and filtration technology to effectively separate the extracellular membrane vesicles loaded with bFGF protein from Escherichia coli without Escherichia coli cells. The extraction method is simple and easy to operate, and the yield of extracellular membrane vesicles is greatly improved under the premise of retaining most of the effective biological components of bacterial outer membrane vesicles. At the same time, the method effectively removes the live bacterial cells of Escherichia coli, ensures the safety of the body, and greatly reduces the risk of bacteremia or scurvy induced by microorganisms entering the blood. In addition, the OMV / FGF2 extracted by the method was applied to colitis wounds, and it was found that it could significantly promote the healing of colitis wounds.

The present invention relates to the field of antimicrobial agents, and in particular to quaternized β-carboline compounds, pharmaceutical compositions thereof, and antimicrobial uses. The present invention provides a quaternized β-carboline compound, the MIC value of which against MRSA is 0.25 to 1 μg / mL, which is stronger than the clinical first-line drug vancomycin, and can be used to treat infectious diseases caused by MRSA such as bacteremia, pneumonia, myocarditis, wound infection, bone and joint infection, etc., and can provide more options for solving the increasingly serious problem of MRSA resistance.

The present disclosure provides immunogenic compositions comprising at least one recombinant polypeptide antigen derived from an Enterococcus bacterium (e.g., E. faecalis, E. faecium, E. durans). The disclosure further provides methods, and uses of the immunogenic compositions, for protecting or treating a subject from infection by an Enterococcus bacterium. Such infections may cause, or worsen, conditions such as root canal failure, endocarditis, bacteremia, urinary tract infections, prostatitis, intraabdominal infection, cellulitis, dysbiotic gastrointestinal tract, prosthetic joint infection, or wound infections.

The present invention belongs to the field of microbiology and specifically relates to a phage composition, its application, and pharmaceutical composition. The phage composition comprises the following phages: ФEBU8, ФECL22, and ФEBU30. The present invention highlights the critical importance of early treatment in the treatment of Enterobacter cloacae bacteremia using a phage cocktail, while prophylactic administration may offer the opportunity to delay treatment and salvage bacteremia.

The present application belongs to the field of medicine and health, and relates to the use of lipoteichoic acid (LTA) and / or lipopolysaccharide (LPS) positive extracellular vesicles in plasma in the detection of bacterial inflammation and / or bacteremia. Specifically, the present application provides an in vitro method for detecting bacterial inflammation and / or bacteremia, comprising the following steps: providing a sample to be tested from a subject; isolating extracellular vesicles from the sample to be tested; detecting the level of LPS positive extracellular vesicles (LPS + EVs) and / or the level of LTA positive extracellular vesicles (LTA + EVs); if the levels of LPS + EVs and / or LTA + EVs increase, it indicates that the subject has bacterial inflammation and / or bacteremia.

The invention discloses a method and a kit for rapidly separating and identifying bacteria in blood of a bacteremia patient, belongs to the technical field of bacteria detection, and aims to solve the problems of low separation efficiency, long time consumption and poor specificity in the existing bacteria separation and enrichment technology. Magnetic particles with inert material coatings are prepared aiming at G-bacteria and G + bacteria in blood of a bacteremia patient, the G-bacteria and the G + bacteria are captured by utilizing the specificity of the magnetic particles, then separation or enrichment culture is carried out on a compound of the magnetic particles and the bacteria after erythrocyte splitting decomposition and centrifugation are carried out to remove impurities, and the compound of the magnetic particles and the bacteria is obtained. Therefore, efficient sorting and enrichment of bacteria in the blood sample of the bacteremia patient are realized. The inert coating on the surface of the magnetic particle reduces the steps of non-specific adsorption, specific binding of the antibody to bacteria and splitting decomposition of red blood cells, so that impurity interference is remarkably reduced; the treatment time is obviously shortened, and the enrichment efficiency is enhanced.

Hematological parameters, such as monocyte distribution width (MOW) and neutrophil to lymphocyte ratio (NLR) may be used for bacteremia screening. Such screening may be performed using a transducer module which comprises an interrogation zone, an illumination source configured to illuminate the blood sample in the interrogation zone, and at least one light sensor configured to detect illumination from cells from a blood sample in the interrogation zone. With such a transducer module, a screening method may be performed which comprises presenting the blood sample to the transducer module, delivering a hydrodynamically focused stream of the blood sample to the interrogation zone of the transducer module, determining one or more white blood cell population parameters for the blood sample based on measurements from the transducer module, and screening the blood sample for bacteremia using a data processing module.

The invention discloses a copper-iron nanocrystalline material, a preparation method thereof and application of the copper-iron nanocrystalline material in treatment of bacteremia. In the material, the molar ratio of copper to iron is 8: 2, CuO and Fe3O4 form a bicrystal structure, and the surface of the material is modified with a stabilizer containing peroxide groups. By accurately regulating and controlling the metal proportion, it is found for the first time that when the ratio of Cu to Fe is 8: 2, the membrane damage capacity of Cu < 2 + > and the Fenton catalytic activity of Fe < 2 + > / Fe < 3 + > generate a remarkable synergistic interaction effect. An antibacterial mechanism shows that the material is adsorbed on the surfaces of bacteria with negative electricity through electrostatic interaction, the integrity of cell membranes is damaged, and intracellular substances are leaked; the peroxy group on the surface can be used as an endogenous H2O2 source to generate a large amount of hydroxyl radicals under the catalysis of Fe < 2 + > to trigger oxidative stress damage in bacteria, so that efficient killing of methicillin-resistant staphylococcus aureus and other drug-resistant bacteria is realized. In-vivo and in-vitro experiments prove that the material has excellent safety performance, can be used as a biomedical material for treating bacteremia, pneumonia and other infectious diseases caused by MRSA, and provides a new choice for solving the problem of MRSA drug resistance.

This invention relates to a Klebsiella pneumoniae mRNA molecule and its application in mRNA vaccines. This invention constructs multiple molecules encoding Klebsiella pneumoniae (… Klebsiella pneumoniae The mRNA of the antigen was extracted and its molecular sequence was optimized to ensure efficient antigen translation. The mRNA sequence is shown in any one of SEQ ID NO. 9-12. A Klebsiella pneumoniae mRNA vaccine was constructed based on a liposome nanoparticle delivery system. The mRNA vaccine can mediate a highly efficient adaptive immune response, effectively induce the activation of the Th17 / Tc17 axis in the lungs and spleen, which is beneficial to the mucosal defense and cell bactericidal mechanism of Klebsiella pneumoniae. It can establish a resident T cell memory bank in the respiratory tract, support long-term and highly effective protection, significantly reduce the risk of colonization and bacteremia, and inhibit the pro-inflammatory cascade. It also shows broad-spectrum and highly effective protection in multiple serotypes of Klebsiella pneumoniae.

The invention discloses an application of host-derived aFRK mRNA in preparation of drugs for resisting bacteremia caused by drug-resistant staphylococcus aureus. MRNA of mouse-derived FRK activated mutant protein aFRK is synthesized in vitro and is introduced into a host cell through a lipid nanoparticle (LNP) delivery system, and the host-derived aFRK mRNA can be used for preparing drugs for resisting bacteremia caused by drug-resistant staphylococcus aureus. The macrophage can obviously enhance the killing ability of the macrophage on intracellular drug-resistant staphylococcus aureus, listeria monocytogenes and salmonella, so that infectious bacteria are effectively removed, bacteremia symptoms are improved, the survival rate is increased, and the macrophage has important clinical application value.

The invention provides an antibacterial carbon dot for treating bacteremia, and the antibacterial carbon dot has application potential in bacteremia treatment. The antibacterial carbon dots are prepared through a precise nano synthesis technology, and have unique physicochemical properties and excellent antibacterial activity. Specifically, the average particle size of the prepared antibacterial carbon dots is 2.0 + / -0.5 nanometers (nm), and the tiny size endows the antibacterial carbon dots with good biocompatibility and efficient cell penetrating power. Meanwhile, the hydrated particle size is 2.2 + / -0.4 nm, which shows that the nano-silver powder has good dispersion stability in an aqueous solution, and is beneficial to wide distribution and action in vivo and in vitro. Besides, the Zeta potential of the antibacterial carbon dot is as high as 36.3 + / -1.5 mV (mV), and the positive potential not only enhances the charge stability of the surface, but also contributes to interaction with negatively charged bacterial cell membranes, thereby enhancing the antibacterial effect.

This invention relates to the field of pharmaceutical synthesis technology, specifically disclosing a 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative and its general structural formula; it also discloses the preparation method and application of this derivative. This 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative exhibits good inhibitory and bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA) and can be used to prevent and treat diseases caused by MRSA infection. Preferably, these diseases include, but are not limited to, pneumonia, urinary tract infections, bacteremia, sepsis, and suppurative arthritis caused by MRSA in humans and animals. The beneficial effects of this invention are: the 1,3-diamino-7H-pyrrolo[3,2-f]quinazoline derivative of this invention is obtained through a four-step reaction, the preparation method is simple, and the reaction conditions are mild; it has good inhibitory and bactericidal activity against MRSA and can be used to prevent and treat diseases caused by MRSA infection.

To solve the problem that sepsis is a disease with a high mortality rate, among these, those caused by gram-negative bacteria have a particularly poor prognosis, and it is necessary to diagnose them early and provide appropriate treatment, however, there is no other method for quickly diagnosing bacteremia, which is one of the causes of sepsis, other than detecting endotoxin.SOLUTION: In the present invention, the existence of gram-negative bacteria floating in LRP is investigated by obtaining a sample containing plasma and a white blood cell, i.e. LRP, under two conditions of 37°C and 0°C using a blood sample.SELECTED DRAWING: Figure 2

The present invention relates to providing an aqueous ticagrelor solution for intravenous administration for use in the treatment of Gram-positive bacterial infections in the bloodstream of a patient in need thereof. The pharmaceutical composition is beneficial to further improving the effectiveness of bacteremia treatment, especially the effectiveness of MSSA and MRSA bacteremia and thrombocytopenia related to bacteremia.

The invention relates to a kit for rapidly identifying the enzyme type of carbapenemase of bacteremia of enterobacter sp. Capable of producing carbapenemase and application of the kit, and relates to the technical field of biological detection. The kit comprises imipenem and any one of avibactam sodium, revobactam and 2, 6-dipicolinic acid, and is characterized in that the kit comprises imipenem and any one of avibactam sodium, revobactam and 2, 6-dipicolinic acid. Compared with the prior art, the method has the advantages of high speed, high accuracy, few interference factors, low cost (less than 1 dollar) and the like when being used for detecting the carbapenemase enzyme type of the carbapenemase-producing enterobacter bacteremia, the survival rate of a patient suffering from the carbapenemase-producing enterobacter bacteremia can be remarkably increased, the hospitalization time is shortened, and the method is suitable for popularization and application. Hospitalization cost is reduced, and great economic and social benefits are achieved.

The invention discloses a medical pus suction device, and relates to the technical field of medical instruments, the medical pus suction device comprises a pus suction assembly and a negative pressure generation assembly, the negative pressure generation assembly is connected with a pus storage assembly, the pus storage assembly is connected with the pus suction assembly, the pus suction assembly comprises a pus suction head and an incision part, and the incision part is arranged on the pus suction head. According to the medical pus suction device, the pus suction head can rapidly and aseptically cut the abscess surface and efficiently suck pus, the pus suction time is greatly shortened, the operation process is simplified, and the treatment efficiency is improved. And the negative pressure can be gradually and accurately adjusted through negative pressure generation, so that the device adapts to different patients and abscess conditions, and the risk of injury to tissues is reduced. The device is suitable for sucking nidus pus of patients with furuncle, carbuncle and sepsis, different nidus sizes can cope with different sizes of pus storage assemblies, the treatment efficiency is improved, and bacteremia and sepsis are reduced from the source.